To explore the expression pattern of CALU across multiple cancers, we utilized the Tumor IMmune Estimation Resource(TIMER) (https://cistrome.shinyapps.io/timer/) (Fig. 1A) and SangerBox (http://sangerbox.com/) (Fig S1A) to discover upregulation of CALU in various malignancies, including LUAD, Breast Cancer (BRCA), Head and Neck Squamous Cancer (HNSC). This evidence concerns the gene CALU and breast cancer.